StreetInsider.com News Articles

ArriVent BioPharma (AVBP) Reiterated at Overweight by Cantor Fitzgerald

Tue, 02 Jun 2026 07:21:46 -0400

Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating on ArriVent BioPharma (NASDAQ: AVBP).

The analyst commented, "ArriVent's (AVBP, OW) firmonertinib was the audience's favorite ex20ins 1L NSCLC treatment despite ongoing investor debate on trial success. Both panelists expect firmonertinib's Ph3 trial in ex20ins to succeed (top-line mid-year), though one noted the opportunity in atypical/PACC mutations is more exciting. There are questions of how to sequence TKIs with SoC ami + chemo, which seems to be a good regimen. Firmonertinib is also viewed as a safer drug than Dizal's (NC) sunvozertinib (Ph3 data at ASCO), which is still not commercially available

ArriVent BioPharma (AVBP) Reiterated at Overweight by Cantor Fitzgerald

Tue, 02 Jun 2026 07:19:39 -0400

Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating and {REMOVEPT} price target on ArriVent BioPharma (NASDAQ: AVBP).

The analyst commented, "Currently, our KOL uses amivantmab (ami, EGFRxcMET bispecific) + chemotherapy for patients with ex20ins EGFR-mutant NSCLC. However, he noted that an unmet need remains for an oral TKI. In his view, sunvozertinib's (Dizal) 10.3 mos PFS in the Ph3 WU-KONG28 trial at ASCO is on par with ami + chemo on efficacy, and if he could get the drug, he would use it in 100% of his patients. He views AVBP's firmonertinib as an efficacious molecule with better tolerability than

Truist Securities Assumes ArriVent BioPharma (AVBP) at Buy

Fri, 29 May 2026 06:07:25 -0400

Truist Securities analyst Supawat Thongthip assumes coverage on ArriVent BioPharma (NASDAQ: AVBP) with a Buy rating and a price target of $45.00.

For an analyst ratings summary and ratings history on ArriVent BioPharma click here. For more ratings news on ArriVent BioPharma click here.

Shares of ArriVent BioPharma closed at $26.97 yesterday.

ArriVent BioPharma (AVBP) PT Lowered to $43 at Citi

Tue, 12 May 2026 09:59:42 -0400

Citi analyst Yigal Nochomovitz lowered the price target on ArriVent BioPharma (NASDAQ: AVBP) to $43.00 (from $45.00) while maintaining a Buy rating.

ArriVent BioPharma, Inc. (AVBP) Misses Q1 EPS by 12c

Mon, 11 May 2026 17:11:16 -0400

ArriVent BioPharma, Inc. (NASDAQ: AVBP) reported Q1 EPS of ($0.96), $0.12 worse than the analyst estimate of ($0.84).

For earnings history and earnings-related data on ArriVent BioPharma, Inc. (AVBP) click here.

ArriVent BioPharma enters $250 million stock offering agreement

Mon, 11 May 2026 16:44:27 -0400

ArriVent BioPharma Inc. (NASDAQ: AVBP) announced it has entered into an Open Market Sale Agreement with Jefferies LLC to serve as sales agent for a potential stock offering worth up to $250 million.

Under the agreement terms, ArriVent may offer and sell shares of its common stock from time to time through Jefferies as its agent, according to a company statement. The arrangement allows the biopharmaceutical company to access capital markets as needed rather than through a single large offering.

The stock sales will be conducted under a prospectus supplement and accompanying base prospectus. ArriVent did not specify timing for when shares

ArriVent BioPharma enters $250 million stock offering agreement

Mon, 11 May 2026 16:44:27 -0400

ArriVent BioPharma Inc. (NASDAQ: AVBP) announced it has entered into an Open Market Sale Agreement with Jefferies LLC to serve as sales agent for a potential stock offering worth up to $250 million.

The stock sales will be conducted under a prospectus supplement and accompanying base prospectus. ArriVent did not specify timing for when shares

Form 8-K ArriVent BioPharma, Inc. For: May 11

Mon, 11 May 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260511/26470037.html

Form 8-K ArriVent BioPharma, Inc. For: May 11

Mon, 11 May 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260511/26470037.html

Form 424B5 ArriVent BioPharma, Inc.

Mon, 11 May 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260511/26469994.html

Form 424B5 ArriVent BioPharma, Inc.

Mon, 11 May 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260511/26469994.html

Form 10-Q ArriVent BioPharma, Inc. For: Mar 31

Mon, 11 May 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260511/26469096.html

Form 10-Q ArriVent BioPharma, Inc. For: Mar 31

Mon, 11 May 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260511/26469096.html

Form 8-K ArriVent BioPharma, Inc. For: May 11

Mon, 11 May 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260511/26468976.html

Form 8-K ArriVent BioPharma, Inc. For: May 11

Mon, 11 May 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260511/26468976.html

ArriVent BioPharma Reports First Quarter 2026 Financial Results

Mon, 11 May 2026 16:01:00 -0400

Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026
IND clearance of ARR-002, ArriVent’s dual-targeting MUC16/NaPi2b tetravalent ADC, advances into the clinic and plans to dose its first patient in 2H 2026, initially for ovarian and endometrial cancers
ARR-002’s superior anti-tumor activity and favorable tolerability vs. single-target or bivalent approaches in preclinical ovarian cancer models presented at AACR
Cash and investments of $326.4 million as of March 31, 2026 expected to fund operations into 4Q 2027